Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Zhonghua Wei Chang Wai Ke Za Zhi ; 26(12): 1202-1209, 2023 Dec 25.
Article in Chinese | MEDLINE | ID: mdl-38110285

ABSTRACT

The current treatment strategy for rectal cancer is a comprehensive treatment centered on surgery. The application of total mesorectal excision (TME) has significantly reduced the local recurrence rate and improved the survival prognosis, but a series of pelvic organ dysfunction caused by pelvic autonomic nerve injury during the operation will reduce the postoperative quality of life of patients. Pelvic autonomic nerve preserving (PANP) radical proctectomy has emerged, but the biggest challenge in the implementation process of this technology is the accurate identification of nerves. A series of studies have shown that pelvic intraoperative autonomic monitoring (pIONM) can effectively assist surgeons to identify nerves, The purpose of this article is to introduce the function of pelvic autonomic nerve, the clinical manifestation of postoperative pelvic dysfunction and its relationship with nerve injury, the key points of implementing PANP, and the current situation and research progress of pIONM technology application.


Subject(s)
Quality of Life , Rectal Neoplasms , Humans , Rectal Neoplasms/surgery , Autonomic Pathways/surgery , Pelvis/surgery , Pelvis/innervation , Autonomic Nervous System/surgery , Autonomic Nervous System/injuries , Rectum/surgery
2.
Zhonghua Liu Xing Bing Xue Za Zhi ; 43(6): 841-845, 2022 Jun 10.
Article in Chinese | MEDLINE | ID: mdl-35725339

ABSTRACT

Objective: To investigate the infection rate in close contacts of COVID-19 patients before and after the last negative nucleic acid test, evaluate the effect of dynamic nucleic acid test in determining the infectivity of COVID-19 patients. Methods: Dynamic nucleic acid test results of COVID-19 cases were collected in a retrospective cohort study. COVID-19 cases with negative nucleic acid test results before their first positive nucleic acid tests were selected as study subjects. Close contacts of the index cases and the secondary close contacts were kept isolation for medical observation to assess their risk of infection. Results: This study included 89 confirmed cases from two local COVID-19 epidemics in Ningbo. A total of 5 609 close contacts were surveyed, the overall infection rate was 0.20%. No close contacts of the COVID-19 cases before the last negative nucleic acid test were infected, and the infection rate in the close contacts of the COVID-19 cases after the last negative nucleic acid test was 1.33%, all of these close contacts lived together with the index cases. No secondary close contacts were infected. Conclusion: COVID-19 patient becomes infectious after the last nucleic acid is negative, and has no infectivity before the last nucleic acid negative.


Subject(s)
COVID-19 , Epidemics , Nucleic Acids , COVID-19/epidemiology , Humans , Retrospective Studies , SARS-CoV-2
3.
Article in English | MEDLINE | ID: mdl-27430483

ABSTRACT

The purpose of this meta-analysis was to evaluate the efficacy of denosumab, compared with zoledronic acid (ZA), in delaying skeletal-related events (SREs) and enhancing overall survival in patients with advanced solid tumours and bone metastases. A systematic literature search of several electronic databases, including PubMed, Medline, Embase, the Cochrane Library, CKNI and Web of Science with Conference Proceedings, was performed. Only randomised controlled trials assessing denosumab in comparison with ZA, in patients with advanced solid tumours and metastatic-stage disease, were included. The primary outcome was the time to first SRE. The risk of developing subsequent on-study SREs and overall survival were also evaluated. Three randomised controlled trials with a total of 5,544 patients with advanced solid tumours and bone metastases were included in the meta-analysis. There were 2,776 patients treated with denosumab and 2,768 treated with ZA. The pooled analysis showed that denosumab was superior to ZA in delaying time to first on-study SRE (odds ratio [OR]: 0.82; 95% CI: 0.75-0.89, p < 0.0001) and multiple SREs (risk ratio: 0.81; 95% CI: 0.74-0.88, p < 0.0001). However, no significant difference was found in overall survival improvement between denosumab and ZA (OR: 1.02; 95% CI: 0.91-1.15, p = 0.71). This meta-analysis indicates that denosumab is superior to ZA in delaying SREs for patients with bone metastases. No significant difference was observed between denosumab and ZA, regarding overall survival. We support denosumab as a potential novel treatment option for the management of bone metastases in advanced solid tumours.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/drug therapy , Denosumab/therapeutic use , Diphosphonates/therapeutic use , Fractures, Spontaneous/prevention & control , Hypercalcemia/prevention & control , Imidazoles/therapeutic use , Spinal Cord Compression/prevention & control , Bone Neoplasms/complications , Bone Neoplasms/secondary , Breast Neoplasms/pathology , Female , Fractures, Spontaneous/etiology , Humans , Hypercalcemia/etiology , Male , Orthopedic Procedures , Prostatic Neoplasms/pathology , Radiotherapy , Spinal Cord Compression/etiology , Zoledronic Acid
4.
J Mol Biol ; 313(5): 1181-93, 2001 Nov 09.
Article in English | MEDLINE | ID: mdl-11700073

ABSTRACT

Molecular analysis of CCR5, the cardinal coreceptor for HIV-1 infection, has implicated the N-terminal extracellular domain (N-ter) and regions vicinal to the second extracellular loop (ECL2) in this activity. It was shown that residues in the N-ter are necessary for binding of the physiologic ligands, RANTES (CCL5) and MIP-1 alpha (CCL3). vMIP-II, encoded by the Kaposi's sarcoma-associated herpesvirus, is a high affinity CCR5 antagonist, but lacks efficacy as a coreceptor inhibitor. Therefore, we compared the mechanism for engagement by vMIP-II of CCR5 to its interaction with physiologic ligands. RANTES, MIP-1 alpha, and vMIP-II bound CCR5 at high affinity, but demonstrated partial cross-competition. Characterization of 15 CCR5 alanine scanning mutants of charged extracellular amino acids revealed that alteration of acidic residues in the distal N-ter abrogated binding of RANTES, MIP-1 alpha, and vMIP-II. Whereas mutation of residues in ECL2 of CCR5 dramatically reduced the binding of RANTES and MIP-1 alpha and their ability to induce signaling, interaction with vMIP-II was not altered by any mutation in the exoloops of the receptor. Paradoxically, monoclonal antibodies to N-ter epitopes did not block chemokine binding, but those mapped to ECL2 were effective inhibitors. A CCR5 chimera with the distal N-ter residues of CXCR2 bound MIP-1 alpha and vMIP-II with an affinity similar to that of the wild-type receptor. Engagement of CCR5 by vMIP-II, but not RANTES or MIP-1 alpha blocked the binding of monoclonal antibodies to the receptor, providing additional evidence for a distinct mechanism for viral chemokine binding. Analysis of the coreceptor activity of randomly generated mouse-human CCR5 chimeras implicated residues in ECL2 between H173 and V197 in this function. RANTES, but not vMIP-II blocked CCR5 M-tropic coreceptor activity in the fusion assay. The insensitivity of vMIP-II binding to mutations in ECL2 provides a potential rationale to its inefficiency as an antagonist of CCR5 coreceptor activity. These findings suggest that the molecular anatomy of CCR5 binding plays a critical role in antagonism of coreceptor activity.


Subject(s)
Chemokine CCL5/metabolism , Chemokines/metabolism , HIV-1/metabolism , Macrophage Inflammatory Proteins/metabolism , Receptors, CCR5/chemistry , Receptors, CCR5/metabolism , Viral Envelope Proteins/metabolism , Alanine/genetics , Alanine/metabolism , Amino Acid Substitution , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Binding, Competitive , CCR5 Receptor Antagonists , CHO Cells , Chemokine CCL3 , Chemokine CCL4 , Chemokine CCL5/antagonists & inhibitors , Chemokines/antagonists & inhibitors , Chemokines/chemistry , Cricetinae , Glycoproteins/metabolism , Humans , Ligands , Macrophage Inflammatory Proteins/antagonists & inhibitors , Mice , Models, Molecular , Mutation , Protein Binding/drug effects , Protein Structure, Tertiary , Receptors, CCR5/genetics , Recombinant Fusion Proteins/antagonists & inhibitors , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Signal Transduction , Structure-Activity Relationship , Substrate Specificity , Tumor Cells, Cultured
5.
J Virol ; 74(24): 11858-72, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11090186

ABSTRACT

The evolution of human immunodeficiency virus type 1 infection is associated with a shift in the target cell population, driven by variability in coreceptor utilization resulting from diversity in env. To elucidate the potential consequences of these changes for Env-mediated fusion over the course of AIDS, we examined the biological properties of serial viral isolates and determined coreceptor utilization by the products of env cloned from two individuals, followed from the detection of seroconversion throughout the course of their infection. One had a typical course, and the other had an accelerated progression. Early isolates were non-syncytium inducing, and the corresponding Env exclusively utilized CCR5, whereas Env from late phases of infection showed restricted utilization of CXCR4 in both patients. Env from subject SC24, who had a standard progression, demonstrated multitropism, manifested by utilization of CCR3, CXCR4, and CCR5 in the intervening period. In contrast, Env from patient SC51, who experienced early conversion to the syncytium-inducing phenotype, developed dualtropic coreceptor utilization of CCR5 and CXCR4. Genetic analysis of env from each isolate revealed that those with an X4 phenotype formed a distinct subcluster within each subject. Analysis of chimeras constructed from R5 and multispecific env from patient SC24 demonstrated that while the V3 domain played a dominant role in determining coreceptor utilization, sequences in the V4-V5 region also contributed to the latter phenotype. Immunoprecipitation experiments confirmed that the hybrid Env proteins were expressed at similar levels. These experiments demonstrate that progression from the R5 to X4 phenotype may occur through a multi- or dual-tropic intermediate and that multiple domains contribute to this process.


Subject(s)
Acquired Immunodeficiency Syndrome/virology , Genome, Viral , HIV-1/genetics , Receptors, Virus/genetics , Viral Envelope Proteins/genetics , Amino Acid Sequence , Evolution, Molecular , Gene Expression Regulation, Viral , Humans , Molecular Sequence Data , Phylogeny
SELECTION OF CITATIONS
SEARCH DETAIL
...